Phaseline

Companies › Immatics Biotechnologies

Immatics Biotechnologies: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IMA401
TCER® (T cell engineered receptor) targeting MAGE-A4 and/or MAGE-A8
MAGE-A4, MAGE-A8Phase 1Refractory CancerSep 2027
IMA402
T Cell-Engaging Receptor Molecule (TCER®)
–Phase 1Refractory CancerSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05958121IMA402Phase 1Refractory CancerOncologySep 2027
NCT05958121IMA401Phase 1Refractory CancerOncologySep 2027
NCT05359445IMA401Phase 1Refractory CancerOncologyDec 2029

Targets

MAGE-A4 (1) MAGE-A8 (1)

Companies with the same targets

USWM CT

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.